Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Megapharmas Will Flee from Japan Unless Gov't Promotes Industry: Mr Dunoyer
November 30, 2009
- Pfizer Embarks on Generics Business in Japan
November 30, 2009
- Taisho Acquires BMS's OTC Drugs Business in Asia, Pacific
November 30, 2009
- Seikagaku: Sales Up 4.6% Driven by Mainstay Products
November 23, 2009
- GRU WG Reviews Gov't Projects for Saving
November 23, 2009
- Tsumura: Record-High Profits Due to Good Sales of Kampo Medicines
November 23, 2009
- Re-price Long-Listed Drugs Looking at Prices of Generics: WG
November 23, 2009
- Meiji Seika: Pharma Business Up 3.2% Driven by Generics
November 23, 2009
- No Conclusion on 2% Price Adjustment Range
November 23, 2009
- Astellas Licenses Linaclotide from Ironwood
November 23, 2009
- Chuikyo Members Split about How to Respond to GRU WG's Recommendation
November 23, 2009
- Nippon Kayaku Licenses Apaziquone from Spectrum
November 23, 2009
- FPMAJ's Proposal Is a Package Deal: Mr Hasegawa
November 23, 2009
- Top-Five Wholesalers'Operating Profits Down 19% Despite 6.6% Increase in Sales
November 23, 2009
- Mr Miura to Represent Pharmacists Because of His Business Experience at Hospital
November 23, 2009
- Banyu to Recommend Januvia in First-Line Therapy
November 23, 2009
- Novartis Applies for New-Type Influenza Vaccine
November 23, 2009
- Plavix Drives Business of sanofi-aventis in Japan: President P. Chocat
November 23, 2009
- Haruo Naito Appointed as President of the IFPMA
November 23, 2009
- Seibule Approved for Combination with Biguanides
November 23, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…